<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116307</url>
  </required_header>
  <id_info>
    <org_study_id>UHID-03</org_study_id>
    <nct_id>NCT04116307</nct_id>
  </id_info>
  <brief_title>Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis</brief_title>
  <official_title>Comparison of Clinical Efficacy of Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital for Infectious Diseases, Croatia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital for Infectious Diseases, Croatia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a new drug, new enteroadsorbent polymethylsiloxane (Enterosgel) in the
      treatment of rotavirus gastroenteritis in children. Half of the participants received a new
      drug, polymethylsiloxane and half of the participants received standard treatment - probiotic
      L. reuteri (BioGaia).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polymethylsiloxane and probiotic L. reuteri both hasten symptoms of the rotavirus
      gastroenteritis but they do so by a different mode of action.

      Polymethylsiloxane is an enteroadsorbent and it possibly acts by adsorption of viruses and
      doing so it prevents binding rotaviruses for enterocytes. Another mode of action can be
      forming a thin layer over the mucosal surfaces thus protects them from various damaging
      factors.

      Probiotics help the healing of the intestinal mucosa presumably in few ways - by
      normalization of gut flora, by competition with pathogen bacteria for binding sites and
      nutrients and by stimulation of intestinal immune system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroenteritis symptoms duration.</measure>
    <time_frame>1-8 days.</time_frame>
    <description>Duration of the loose stools, fever and vomiting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the hospitalization of any kind.</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of the classic hospitalization or duration of daily hospital attending.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of loose stools.</measure>
    <time_frame>8 days</time_frame>
    <description>The total number of loose stools are measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Polymethylsiloxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polymethylsiloxane (Enterosgel) is given 3 x 10 g for the initial two days, and 3 x 5 g for the next three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic Lactobacillus reuteri (BioGaia) is given 3 x 20 drops (which means 3 x 400,000.000 CFU) per day for five days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polymethylsiloxane</intervention_name>
    <arm_group_label>Polymethylsiloxane</arm_group_label>
    <other_name>Enterosgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri</intervention_name>
    <arm_group_label>Lactobacillus reuteri</arm_group_label>
    <other_name>BioGaia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 6-36 months

          2. proven rotavirus gastroenteritis

          3. symptom duration less than 48 hours

          4. informed consent of the parents/caregivers

        Exclusion Criteria:

          1. rotavirus vaccination

          2. rotavirus infection in a patient's history

          3. severe acute or chronic illness with possible influence on rotavirus gastroenteritis
             outcome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Tešović, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic for Infectious Diseases, Zagreb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic for Infectious Diseases</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data are available for ten years.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

